Quantcast
Last updated on April 16, 2014 at 6:04 EDT

Latest Sofinnova Stories

2012-01-05 07:30:00

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2012 /PRNewswire/ -- Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced that Pfizer Inc. has initiated a Phase 1 clinical trial for PF-05280602, an investigational proprietary, engineered variant of recombinant human Factor VIIa developed by Catalyst Biosciences. PF-05280602 has been engineered to provide improved acute and prophylactic treatment for hemophilia A...

2011-10-04 02:00:00

LUXEMBOURG, October 4, 2011 /PRNewswire/ -- Funds to Advance Development of Creabilis' First-in-Class Products Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, has raised EUR15 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures. Existing investors Neomed and Sofinnova Partners, as well as private Italian investors,...

2011-09-29 10:37:00

DURHAM, N.C., Sept. 29, 2011 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today that its Chief Executive Officer, Thomas P. Mathers, will be making a company presentation at the Sofinnova Japan Biopharma Partnering Conference at 9:35 - 10:00 a.m. on Tuesday, October 4th, 2011 in the Nami room at the Conrad Hotel in Tokyo, Japan. The partnering meeting is expected to attract over 300 participants from around the globe including business...

2011-09-28 09:17:00

BASKING RIDGE, N.J., Sept. 28, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Sofinnova Japan Biopharma Partnering Conference at 2:50 p.m. JST on October 4, 2011 in Tokyo, Japan. The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative...

2011-07-18 06:00:00

BRISBANE, Calif., July 18, 2011 /PRNewswire/ -- SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing. The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners. (Logo: http://photos.prnewswire.com/prnh/20110718/FL36481LOGO ) "We believe that SARcode is uniquely positioned...

2011-06-30 06:00:00

SUNNYVALE, Calif., June 30, 2011 /PRNewswire/ -- Sorbent Therapeutics, a private biopharmaceutical company developing therapies for cardiovascular and renal disorders, announced today that it has expanded the Company's Series B financing from September 2010 by $36 million. This brings the total proceeds of the Company's second financing round to $53 million. New investor Novartis Venture Funds led this financing, joining existing investors Sofinnova Ventures, ARCH Venture Partners, CMEA...

2011-06-22 03:00:00

CAMBRIDGE, England, June 21, 2011 /PRNewswire/ -- Crescendo Biologics Limited (Crescendo) today announces the appointment of Matthew Roe as Chief Business Officer. Matthew joins Crescendo from Genzyme Corporation where he was Senior Director, Business Development & Licensing. During a 23-year career at Genzyme, Matthew was active in licensing, alliance management, acquisition, divestment, and sales and marketing, and saw the corporation develop from an entrepreneurial...

2011-06-09 06:00:00

AMSTERDAM, The Netherlands, June 9, 2011 /PRNewswire/ -- Avantium is proud to announce that it has successfully raised EUR 30 million to advance its breakthrough YXY technology for green building blocks. Avantium will use the funds for the construction and operation of its pilot plant in Geleen, the Netherlands, and for the development of green materials on basis of these YXY building blocks. Avantium has completed a EUR 25 million financing round with new investors Sofinnova...

2011-05-04 06:00:00

MINNEAPOLIS, MN, May 4 /PRNewswire/ - BioAmber Inc., the market leader in biobased succinic acid, has raised $45 million dollars in a Series B financing that will accelerate the commercialization of succinic acid and modified PBS. The round was led by NAXOS Capital Partners, a European based growth capital fund focused on acquiring and developing businesses with unique intellectual property or market position with a focus on renewable agro and food business, energy and...

2011-03-14 07:35:00

BEDMINSTER, N.J., March 14, 2011 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing. The capital raised will be used to fund the Phase 3 clinical development of Omthera's novel...